Humacyte’s (HUMA) “Buy” Rating Reaffirmed at Benchmark

Benchmark reaffirmed their buy rating on shares of Humacyte (NASDAQ:HUMA) in a research note released on Friday morning, Benzinga reports. They currently have a $15.00 price objective on the stock.

Other equities analysts also recently issued research reports about the company. Cantor Fitzgerald reaffirmed an overweight rating and set a $7.00 price target on shares of Humacyte in a research report on Monday, April 1st. Piper Sandler reaffirmed a neutral rating and issued a $4.00 price objective on shares of Humacyte in a research note on Tuesday, March 26th.

Humacyte Price Performance

Humacyte stock traded down $0.06 during midday trading on Friday, hitting $7.15. The company’s stock had a trading volume of 1,454,939 shares, compared to its average volume of 2,301,377. Humacyte has a 12 month low of $1.96 and a 12 month high of $7.78. The company has a debt-to-equity ratio of 0.61, a current ratio of 8.37 and a quick ratio of 8.37. The stock’s 50-day moving average price is $4.20 and its 200-day moving average price is $3.47.

Humacyte (NASDAQ:HUMA) last released its quarterly earnings data on Friday, March 22nd. The company reported ($0.24) EPS for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.01. During the same quarter in the prior year, the company earned ($0.21) EPS. Sell-side analysts predict that Humacyte will post -0.95 EPS for the current fiscal year.

Insider Buying and Selling at Humacyte

In other Humacyte news, Director Gordon M. Binder purchased 50,000 shares of the company’s stock in a transaction that occurred on Wednesday, May 15th. The shares were acquired at an average cost of $6.78 per share, for a total transaction of $339,000.00. Following the completion of the acquisition, the director now owns 160,000 shares of the company’s stock, valued at approximately $1,084,800. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 23.10% of the company’s stock.

Hedge Funds Weigh In On Humacyte

Several hedge funds have recently made changes to their positions in HUMA. Tower Research Capital LLC TRC boosted its stake in Humacyte by 261.7% during the fourth quarter. Tower Research Capital LLC TRC now owns 8,989 shares of the company’s stock valued at $26,000 after buying an additional 6,504 shares during the period. Whittier Trust Co. of Nevada Inc. bought a new stake in Humacyte during the fourth quarter worth about $28,000. Victory Capital Management Inc. bought a new stake in Humacyte during the fourth quarter worth about $29,000. China Universal Asset Management Co. Ltd. lifted its stake in Humacyte by 350.4% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 11,986 shares of the company’s stock worth $34,000 after purchasing an additional 9,325 shares during the last quarter. Finally, Kovitz Investment Group Partners LLC bought a new stake in Humacyte during the fourth quarter worth about $35,000. 44.71% of the stock is currently owned by hedge funds and other institutional investors.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.